Wei Chen, Ph.D., CEODr. Chen joined NetVation DL Medicine as the chief executive officer and a member of the board of directors. Prior to joining DL Medicine, he has been leading drug discovery efforts at HitGen Ltd, one of DL Medicine's investors. Dr. Chen has more than 20 years' experience in the Biotech and Pharmaceutical industry (Genome Therapeutics, Millennium, Takeda, HitGen) and has had scientific and management roles in drug discovery. Trained as a biochemist/enzymologist, he has broadened his expertise into molecular cell biology and pharmacology during his postdoctoral work at Harvard University. Dr. Chen has participated and led efforts in all stages of drug discovery, from target identification to IND filing, of which several programs are currently in clinical trials. He also has significant experience in translational medicine research, in particular supporting clinical trial efforts.
Steve Faraci, Ph.D., CSODr. Faraci has more than 25 years' experience in large Pharma and Biotech with expertise in screening, lead discovery, formulation and CMC. Recently, Dr. Faraci was Executive Director and Site Head at Capsugel's Product Development Center with a focus on formulation development and clinical manufacturing. Previously, Dr. Faraci worked for over 22 years at Pfizer Global Research & Development in a variety of leadership roles throughout the organization. He was a founding member of the leadership team that helped build a new R&D site in Cambridge, MA in 1999, growing from 10 employees to over 150. He had various leadership roles at the site, including Head of Biology, Interim Site Head and Chief Operating Officer. His responsibilities included internal research and development as well as external academic/industry collaborations. Steve was a member of the Mass Biotech Council Board of Directors. He received his Ph.D. in Chemistry from Wesleyan University and continued his training as a National Institute of Health Postdoctoral Fellow at the Massachusetts Institute of Technology and Harvard Medical School in the laboratory of Professor Christopher Walsh.
Roman Herrera, Ph.D., Senior AdvisorDr. Herrera has worked for over 20 years in large Pharma and Biotech, in particular in vitro and in vivo biology in the areas of Metabolic Disease, Inflammation and Oncology. Dr. Herrera obtained his Ph.D. in Molecular Pharmacology at Albert Einstein Medical College studying the structure-function relationship of the insulin receptor. After post-doctoral training at the Dana Farber Cancer Institute, studying genes linked to cell differentiation, he joined Parke-Davis/Warner Lambert-Pfizer (Ann Arbor, MI/Cambridge/MA) where he worked in drug discovery programs across several disease areas such as inflammation, diabetes and cancer. He assumed increased leadership roles in target identification/validation, in vivo disease models and biomarkers strategies to support both pre-clinical and clinical (Phase I/II) programs.
NetVation DL Medicine has been working with scientific advisors and
collaborators from the Chinese and US academic community
Ning Zheng, Ph.D.Professor, Howard Hughes Medical Institute and Department of Pharmacology, University of Washington, Seattle, Washington. Expert in E3 ligase, molecular and structural mechanisms by which protein ubiquitination controls eukaryotic biology and human diseases.
Chen Dong, Ph.D.Professor, Dean of the School of Medicine, Tsinghua University, Beijing, China. Research involves molecular mechanisms whereby immune and inflammatory responses are regulated, and to apply this knowledge to the understanding and treatment of autoimmunity and allergy disorders as well as cancer.
HitGen LtdHitGen is an innovation driven life science company based in Chengdu, China and Houston, Texas. HitGen has established a unique platform for early drug discovery research, utilizing DNA encoded libraries containing more than 150 billion novel, diverse drug-like compounds. The library is founded on many hundreds of distinct chemical scaffolds, designed with tractable chemistry and proven results for finding drug leads against targets from known and novel protein classes.
AnlongMed FundAnlong Life Sciences Fund (安龙基金) is a Beijing, China based company focused on early-stage investments in the life sciences and healthcare-related fields, such as biotech & pharma, medical devices, life sciences, and medical services.
PfizerAt Pfizer, we apply science and its global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
NetVation DL MedicineWebsite: www.nvdlmed.com